超越化疗:在结直肠癌中探索5-FU耐药性和干性
Ursheeta Singh1, Rekha Rani Kokkanti1, Srinivas Patnaik1
1School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) Deemed to be University, Bhubaneswar, 751024, Odisha, India.
European journal of pharmacology
|January 25, 2025
概括
结肠直肠癌干细胞 (CSCs) 对5-甲 (5-FU) 治疗具有抗性. 免疫疗法和纳米医学等新的策略为克服这种抵抗和改善结直肠癌治疗提供了有希望的途径.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结肠直肠癌 (CRC) 是一个主要的全球健康问题,需要改进治疗方法.
- 结肠直肠癌干细胞 (CSCs) 有助于治疗耐药性,特别是对5-甲 (5-FU).
- 了解CSC耐药机制对于开发有效的CRC疗法至关重要.
研究的目的:
- 审查针对结直肠癌干细胞 (CSCs) 的挑战.
- 探索CRC中5-甲 (5-FU) 耐药性的机制.
- 讨论克服CSC耐药性的新型治疗策略.
主要方法:
- 关于结直肠癌干细胞 (CSC) 和5-甲 (5-FU) 耐药性的当前研究的文献综述.
- 对组合疗法 (例如,FOLFOXIRI) 和向治疗 (例如,贝瓦西祖马布,塞图西马布,帕尼图穆马布) 的分析.
- 对生物标志物的评估 (例如,TYMS,TP,DPD) 以预测治疗反应.
主要成果:
- 在特定患者群体 (KRAS野生型) 中,可以通过组合疗法和向治疗来提高5-FU的疗效.
- 生物标志物在预测5-FU疗效和耐药性方面发挥着关键作用.
- 由于瘤微环境和标记物变异性,CSCs表现出固有的耐药性,这构成了重大挑战.
结论:
- 针对CRC-CSC是复杂的,但对于改善治疗结果至关重要.
- 个性化医学,免疫疗法 (免疫检查点抑制剂,癌症疫苗) 和纳米医学提供了有前途的途径.
- 将创新策略与传统疗法相结合,可以通过解决CSC对5-FU的耐药性来提高CRC治疗的有效性.
相关概念视频
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K